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Opinion Statement
Synovial sarcoma (SS) is a rare, yet highly malignant, type of soft tissue sarcoma (STS), for
which survival has not improved significantly during the past years. In this review, we
focus on systemic treatment in adults. Compared to other STS, SS are relatively
chemosensitive. Ifosfamide and ifosfamide combinations are active in different lines of
treatment. In high-risk extremity and chest wall STS, neoadjuvant doxorubicin and
ifosfamide has shown as much activity as high-dose ifosfamide. There are indications
that combination chemotherapy with doxorubicin and ifosfamide in this setting improves
outcome. In the first-line metastatic setting, combination treatment with doxorubicin and
ifosfamide is a preferred option in fit patients, while in other patients, sequential
doxorubicin and ifosfamide can be considered. In second and later lines, pazopanib and
trabectedin have shown activity. Many new approaches to treat metastatic SS are currently
under investigation, both preclinical as well as clinical, including other receptor tyrosine
kinase inhibitors, epigenetic modulators, compounds interfering with DNA damage re-
sponse (DDR), and immunotherapy.
Introduction
Soft tissue sarcomas (STS) are rare, malignant mesen-
chymal tumors that include over 70 different and highly
diverse histological subtypes. Synovial sarcoma (SS) ac-
counts for 5–10% of all STS [1, 2]. SS is an intriguing
disease as, unlike the majority of STS, it can occur at any
age and everywhere in the body. The peak incidence is in
the 30s and it often presents in the extremities [3•]. The
incidence of SS continued to increase from 0.906 to
1.548 per 1,000,000 between 1983 and 2012 [4]. De-
spite its name, SS does not arise from the synovium,
neither expresses synovial markers [5]. SS was initially
described as a biphasic neoplasm comprising of both
epithelial and uniform spindle cell components. SS is
characterized by the presence of the pathognomonic
t(X;18) (p11.2;q11.2) translocation, involving a fusion
of the SS18 (formerly SYT) gene on chromosome 18 to
one of the synovial sarcoma X (SSX) genes on chromo-
some X (usually SSX1 or SSX2), which is seen in more
than 90% of SS and results in the formation of SS18-SSX
fusion oncogenes [6].
For localized non high-risk disease, treatment
consists of surgery, on indication combined with
(neo)adjuvant radiotherapy. In about 50% of cases,
metastases occur [7]. Interestingly, the prognosis of
primary non metastasized SS is related to the age of
the patient, with a much better relative survival in
children compared to older patients, and more ge-
nomic instability with increasing age [3•, 8]. The 5-
year overall survival (OS) for all SS is 60.5%, but is
largely age-dependent [4].
In most cases, metastases are localized in the lung
(80%), although metastases can arise in lymph nodes
(up to 20%), bone (9.9%), and liver (4.5%) as well [9•,
10]. Once metastasized, curative treatment is hardly
achievable, with the exception of late and resectable
oligometastatic disease and patients are treated with
chemotherapy with a palliative intent. Compared to
STS as a group, SS is more sensitive to certain chemo-
therapeutic agents [9•, 11].
For long, STS have been clinically treated as one
type of disease, and most chemotherapy trials includ-
ed the majority of STS subtypes. The first attempt to
address the differences in tumor behavior led to strat-
ification for leiomyosarcomas, liposarcomas, SS, and
the so-called other group and made use of the 3- and
6-month progression-free rate (PFR) in second- and
higher-line studies [12].
It is only in recent years that more sarcoma subtype-
specific trials are undertaken, recognizing the large di-
versity in clinical behavior, biology, and genetic make-
up of the different STS and appreciating the recent in-
sights in more tumor-specific therapy. We here review
the current standard of care for treatment of advanced
and metastatic SS in adults and provide insights in the
developments within the fields of targeted therapy and
immunotherapy.
Current pharmacological treatment options
Chemotherapy
(Neo)adjuvant chemotherapy
The insights on (neo)adjuvant chemotherapy in STS have excellently been
reviewed very recently [13, 14] and the most important trials are summa-
rized in Table 1. In summary, in adults with localized STS of all localiza-
tions, chemotherapy in an adjuvant setting is not the standard of care,
since many adjuvant STS trials, including SS, ultimately failed to prove
overall survival benefit [20]. Neoadjuvant chemotherapy might be con-
sidered in specific situations, for example as induction therapy to enhance
outcome of surgery in high-risk sarcoma of extremity and chest wall.
Recent data suggest that also DFS may benefit from this approach. In this
respect, two studies in SS are worth mentioning.
A phase II trial exploring neoadjuvant treatment with doxorubicin 60 mg/
m2 and ifosfamide 10 g/m2 for three neoadjuvant and two adjuvant courses in
STS of the extremities, included 20 SS patients out of a total of 70 patients, and
reported 2- and 5-year progression-free survival (PFS) rates of 75.7% (95% CI,
63.9–84.1%) and 63.8% (95% CI, 51.3–73.9%), respectively. The 5-year OS
was 82.6% (95%CI, 71.3–89.7%). Protocol treatments were completed in 74%
of the cases and toxicity was significant [17].
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Table 1. (Neo)adjuvant chemotherapy
(Neo)adjuvant treatment Population Phase Total n (SS) Outcome Year of
publication
Histology-tailored
neoadjuvant
chemotherapy in 5 types
of STS. For SS: high-dose
ifosfamide (14 g/m2
in 14 days) every 28 days
vs. epirubicine
+ ifosfamide 9 g/m2
in 3 days every 21 days
[15••]
SS
LMS
mLPS
MPNST
UPS
III 287 (70) DFS
after 46 months
histology-tailored
chemotherapy
38%
vs. standard group
46%, OS
89% vs. 64%
(both significant,
median follow-up
12.3 months,
70 events)
Subgroup analysis:
standard
chemotherapy
favorable for SS
(HR 1.85, 95% CI
0.65–5.22, 17/70
events)
2017
Doxorubicin 75 mg/m2,
ifosfamide 5 g/m2,
and lenograstim q 3 weeks for
5 cycles adjuvant
vs. active controle. 73%
also had radiotherapy [16]
STS III 351 (40) Median OS 12.4
vs. 11.2 years
(not significant)
5 years EFS: 52.9
vs. 54.9%
5 years OS 67.8
vs. 66.5%
2012
Doxorubicin 60 mg/m2 and
ifosfamide 10 g/m2 for 3
neoadjuvant and 2 adjuvant
courses [17]
STS II 70 (20) 2 years PFS 75.7%
5 years PFS 63.8%
5 years OS 82.6%
2015
Doxorubicin 37.5 mg/m2 for
2 days and ifosfamide 3 g/m2
for 3 days followed by 2 cycles
of ifosfamide 3 g/m2 for
2 days [18]
SS II 138 3 years EFS 81.9%
5 years EFS 80.7%
3 years OS 97.2%
5 years OS 90.7%
2015
Not specified [19] SS stage
I–III
IV 544 pts.
of whom 131
received
chemotherapy
Hazard ratio
chemotherapy for
OS:
- overall cohort:
0.95
(0.63–1.44)
- stage I 4.80
(0.91–25.3)
- stage IIA 1.32
(0.54–3.20)
- stage IIB 0.36
(0.07–1.76)
2017
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Results of a recent study in high-risk STS of extremity and chest wall, support
the role of neoadjuvant combination chemotherapy, because of a gain in
disease-free survival (DFS) [15••]. This study consisted of five cohorts of STS,
with an SS cohort including 70 patients. Patients were randomized 1:1 to three
cycles of standard treatment consisting of ifosfamide 3 g/m2 on days 1–3 and
epirubicin 60 mg/m2 on days 1–2 of every 21 days vs. histology-tailored
chemotherapy, which was in SS high-dose ifosfamide 1 g/m2 on days 1–14 of
every 28 days [15••]. After a median follow-up of 12.3 months for the total
study population (n = 287), the projected DFS at 46 months was 62% (95% CI
48–77) in the standard chemotherapy group and 38% [21••, 22, 23–26, 27•,
28•, 29, 30–37, 38•, 39, 40–44, 45••, 46, 47, 48, 49•, 50, 51, 52•, 53, 54] in the
histotype-tailored chemotherapy group (stratified log-rank p = 0.004; hazard
ratio 2.00, 95% CI 1.22–3.26; p = 0.006). Subgroup analysis indicated no
preference for histology-tailored chemotherapy in the SS cohort (HR 1.85, 95%
CI 0.69–5.22). Final OS data are awaited.
Another risk-adapted approach had been included in a study of the Euro-
pean Pediatric Soft tissue sarcoma Study Group (EpSSG). SS patients G age of
21 years were treated in the EpSSG NRSTS 2005 trial, which included 138
children and adolescents with SS [18]. Treatment was tailored according to risk
group. Low-risk patients (R0 resection, tumor ≤ 5 cm in size) were treated with
surgery alone, intermediate-risk patients (R0 resection and tumor 9 5 cm in size,
or R1 resection) with three to six courses of chemotherapy ± radiotherapy, and
high-risk patients (R2 resection, no resection at all, or N1) were treated with six
cycles of chemotherapy, surgery, and radiotherapy. Chemotherapy consisted of
amaximumof four cycles of doxorubicin 37.5mg/m2 for 2 days and ifosfamide
3 g/m2 for 3 days followed by two cycles of ifosfamide 3 g/m2 for 2 days. After a
median follow-up of 52 months, the 3- and 5-year event-free survival (EFS) for
all risk groups was 81.9 and 80.7%, and the 3- and 5-years OS was 97.2 and
90.7%, respectively. The only significant prognostic variable at univariate
analysis was the risk group: 3-year EFS was 91.7% for low risk, 91.2% for
intermediate risk, and 74.4% for high risk [18].
Palliative chemotherapy
First-line treatment
In STS, doxorubicin is still considered to be the standard first-line systemic
therapy (Table 2), with response rates ranging between 16 and 27% and a
Table 1. (Continued)
(Neo)adjuvant treatment Population Phase Total n (SS) Outcome Year of
publication
- stage III 0.56
(0.33–0.93), p =
0.028
SS synovial sarcoma, STS soft tissue sarcoma, MLPS myxoid liposarcoma, MPNST malignant peripheral nerve sheath tumor, UPS undifferentiated
pleiomorphic sarcoma, DFS disease free survival, OS overall survival, PFS progression free survival, EFS event free survival
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median survival in clinical studies of nowadays approximately 18 months
from start of first-line systemic treatment [62]. In the METAsarc study
analyzing the outcome of 2225 STS patients in the real-life setting, the OS
of the 150 SS pts. who started first-line treatment was 19.7 months [63,
64••]. In 2014, the EORTC STSBG 62012 study compared single-agent
doxorubicin to the combination of doxorubicin and ifosfamide in STS
showing a response rate of 13.6 vs. 26.5%,median progression-free survival
(PFS) of 4.6 vs. 7.4 months and no significant difference in median OS
(12.8 vs. 14.3 months) but significant more adverse events in the combi-
nation arm [21••]. In this trial, 64 out of 455 STS patients had SS (14%),
but no histotype subgroup analysis was done.
As mentioned before, SS are considered to be more chemosensitive as com-
pared to other STS histologies [7]. Sleijfer et al. reviewed ifosfamide in different
EORTC studies and found an increased response rate of ifosfamide in SS
compared to other histologies [11]. A recent EORTC review of 15 clinical STS
trials investigated the outcome of chemotherapy in advanced SS patients, and
included 313 SS patients out of 3330 STS patients. Nine out of these 15 trials
investigated anthracyclines as monotherapy arm (n = 121 SS), 5 a combina-
tion of doxorubicin and ifosfamide arm (n = 112 SS), and 3 an ifosfamide
monotherapy arm (n = 42 SS). The median PFS was significantly higher for SS
patients compared to STS patients (6.3 vs. 3.7months), as was themedianOS
(15.0 vs. 11.7months) and the response rate (27.8 vs. 18.8%). Comparison of
the response rates (combined complete (CR) and partial response (PR)) to the
different chemotherapy schedules showed a response rate of 21.5% for
anthracyclines alone, 32.2% for doxorubicin-ifosfamide, and 33% for
ifosfamide alone. It was concluded that SS patients show superior responses to
chemotherapy compared to STS patients and that, compared to anthracyclines
alone, ifosfamide was (although not significant) the most active drug [9•].
Recently, two large phase III trials in STS patients testing new ifosfamide-
related compounds, namely palifosfamide and evofosfamide, in combi-
nation with doxorubicin vs. doxorubicin alone, reported negative results
[22, 23]. Both trials included 5% SS patients, but unfortunately reported no
further details of this subgroup. Furthermore, a randomized phase II trial
for doxorubicin plus trabectedin vs. doxorubicin alone in the first line was
negative in 115 STS patients, of whom only 7 was with synovial sarcoma
[24]. Very recently, a direct comparison between first-line doxorubicin and
gemcitabine-docetaxel was made by Seddon et al. [25]. Five patients with
synovial sarcoma out of 129 STS patients were treated with doxorubicin
compared to 6 out of 128 patients treated with gemcitabine-docetaxel. After
a median follow-up of 22 months, the median PFS of the total study
populations was 23.3 vs. 23.7 weeks (HR 1.28, 95% CI 0.99–1.65, p =
0.06). The proportion of patients alive and progression-free at 24 weeks did
not differ between those who received doxorubicin vs. those who received
gemcitabine and docetaxel (46.3 vs. 46.4%). The number of synovial
sarcoma patients in this study was too low to draw any significant
conclusions.
In conclusion, in fit patients, data suggest that SS patients might benefit
from first-line combination treatment of ifosfamide with doxorubicin over
monotherapy doxorubicin, although—due to the rarity of the disease—this
conclusion is not based on a prospective randomized study in SS.
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Beyond first-line treatment
Several drugs are available for second-line and further treatment of ad-
vanced and metastatic STS (Table 2). The selection of a specific schedule is
made on the basis of individual patient-based considerations, including
age, performance score, histological subtype, tumor burden, pace of pro-
gression, main aim of treatment, toxicity experienced during first-line
treatment, potential toxicity of the second-line treatment, etc. For SS, the
second-line treatment of first choice for the majority of fit patients is
ifosfamide, based on its known activity in SS. Alternative options are
pazopanib and trabectedin in case patients are not fit enough for ifosfamide
or have received the combination of doxorubicin and ifosfamide in first
line. In some case, ifosfamide monotherapy can be considered after this
first-line combination treatment, in particular when there has been a rea-
sonable interval between the end of first- and start of second-line treatment.
Single-center data on ifosfamide rechallenge in different STS subtypes
showed the highest activity in SS [26]. The role of trabectedin in SS has been
investigated in a Japanese randomized phase II study comparing
trabectedin to best supportive care in translocation-related sarcomas,
showed a significantly better response rate (8 vs. 0%), longer median PFS
(5.6 vs. 0.9 months, HR 0.07), and longer median OS (not reached vs.
8 months, HR 0.42, median follow-up 8.9 months) for the total group
[27•]. Eighteen out of the total of 73 patients had SS. This subgroup had a
median PFS in favor of trabectedin (HR 0.14, 95% CI 0.03–0.68). A
retrospective analysis of 61 SS patients treated with trabectedin in four
European sarcoma reference centers reported a response rate of 15%, a
median PFS of 3 months, and a 6-month PFR of 23% [28•]. Trabectedin in
SS has never been tested in the context of a phase III trial [30]. Eribulin has
also only been tested for SS in a phase II trial. This study included 128
patients in four cohorts, of which one involved the SS subtype, which
included 19 patients. The primary endpoint was PFR at 12 weeks. The study
was regarded positive for a cohort when the 12-week PFR was 9 40% and
negative G 20%. For SS, the 12-week PFR was 21.1%, for leiomyosarcoma
31.6%, and for adipocyte sarcoma 46.9% [29] The phase III trial subse-
quently only included leiomyosarcoma and adipocyte sarcoma [30]. Other
chemotherapeutic options for STS in general include gemcitabine,
dacarbazine, and cyclophosphamide-prednisone, without specific refer-
ences for SS patients [31–33].
Targeted therapy
In the past years, a lot of effort has been put into the design of a more effective
and less toxic treatment modalities in SS patients. At present, however,
pazopanib is still the only targeted drug approved for the treatment of STS,
including SS, in the advanced setting after failure of standard cytotoxic therapy.
Pazopanib is an oral, multi-targeted tyrosine kinase inhibitor directed against
the receptor tyrosine kinases (RTKs) vascular endothelial growth factor
(VEGFR) 1/2/3, platelet-derived growth factor (PDGFR) α/β, and KIT, thereby
blocking tumor growth and inhibiting angiogenesis. In the first multistrata
design with pazopanib in STS, the different PFRs at 3 months were 26% in
adipocytic STS, 44%, in leiomyosarcomas, 49% in SS, and 39% in a stratum of
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other STS [34]. Based on this, the expectations for SS in the phase III study were
high. The landmark PALETTE trial that led to the approval of pazopanib in STS
in the advanced setting examined a total of 369 STS patients (12% SS). Patients
were randomized 2:1 to receive either pazopanib 800mgOD orally or placebo.
Median PFS was significantly longer in the pazopanib-treated group; 4.6 vs.
1.6 months (HR 0.31, 95% CI 0.24–0.40, p G 0.0001), although no significant
difference in median OS was detected (12.5 vs. 10.7 months, HR 0.85, 95% CI
0.67–1.11, p = 0.25). Partial remissions were observed in 6% of patients who
received pazopanib, and another 67% had stable disease (SD) as best response
[35]. For SS, the PFS and OS were promising when compared to other histol-
ogies, but due to the relatively low number of SS, no statistically significant
differences were observed in this subtype. Pazopanib efficacy was also in-
vestigated in a retrospective analysis of the Named Patient Program
called SPIRE study which included 24 SS patients out of 211 STS pa-
tients in total [36]. For the SS patients, the median duration on
pazopanib in this study was 5.1 months and the median OS was
13.8 months. A phase I trial combining pazopanib with ifosfamide
reported a PR in two patients with SS [37].
Novel treatment options under development
Novel targeted therapies in the clinic
In addition to pazopanib, various other (classes of) targeted therapy have
been tested for efficacy in SS, including compounds directed against
RTKs, epigenetic regulators, and immunomodulators. So far, the majority
of preclinical and early promising results have failed to translate suc-
cessfully to the clinic, with generally only short-lasting benefit in a small
fraction of SS patients. However, some recent developments in the clin-
ical and preclinical setting look more promising and will be further
discussed.
(Receptor) tyrosine kinase targeted therapies
As the multi-RTK inhibitor pazopanib is at present, still, the only approved
form of targeted therapy with evidence of clinical efficacy in SS, various
studies examined the potential of targeting (other) RTKs or associated
pathways in SS. To date, the highest clinical efficacy in SS has been
observed for the multikinase VEGFR/PDGFR inhibitor regorafenib. The
REGOSARC trial tested regorafenib 160 mg OD for 21 of each 28 days vs.
placebo in four cohorts of doxorubicin pre-treated STS patients, including
1 SS cohort [38•]. In the SS cohort, PFS was 5.6 months (95% CI 1.4–
11.6) with regorafenib vs. 1.0 (0.8–1.4) with placebo (HR 0.10 (95% CI
0.03–0.35) p G 0.0001) with 1 PR and 10 SDs out of 13 SS patients in the
regorafenib arm. This effect was confirmed with a longer follow-up [39]. In
a phase II trial with sorafenib, 12 SS out of 145 STS patients were treated
with very limited efficacy [40]. Currently, a randomized EORTC phase II
study ANITA comparing the oral angiogenesis inhibitor nintedanib with
ifosfamide in second line is recruiting patients with advanced and meta-
static STS, including SS (NCT02808247).
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A phase III trial with an SS cohort (n = 95) comparing in a 2:1 ratio efficacy
of the multikinase VEGFR/PDGFR inhibitor anlotinib to dacarbazine is cur-
rently recruiting patients (NCT03016819). Four phase II trials with an anti-IGF-
1R-antibody did not show encouraging results in SS [41–44].
In the recent promising phase Ib-II study testing the combination of PDGFR
antibody olaratumab plus doxorubicin vs. doxorubicin alone, only three SS
patients were included [45••]. The phase III ANNOUNCE trial with similar
treatment arms will hopefully have a reasonable subgroup of SS patients.
Results of this study carried out in many STS subtypes, are awaited.
Epigenetic modifiers
The EZH2 inhibitor tazemetostat is currently the most studied epigenetic
modulating drug in SS in the clinic. Tazemetostat activity is enhanced in
integrase interactor 1 (INI1; aka SMARCB1)-negative tumors, in which INI1 loss
allows EZH2 to become an oncogenic driver in tumor cells. INI1 deficiency
specifically linked to the presence of the SS18-SSX1 fusion gene has been
reported in SS in preclinical models [46, 47]. Accordingly, INI1 loss is a
characteristic of SS tumor cell lines and tumors [48]. Preliminary data from
ongoing adult phase I/II (NCT01897571) and phase II (NCT02601950) trials
assessing single-agent tazemetostat activity in a variety of tumors including SS
have confirmed clinical efficacy of tazemetostat in INI1-deficient tumors [49•,
50]. The three included SS patients in the phase I/II trial were, however, not
INI1-negative and showed no response. As SS tumors are INI1-deficient rather
than INI1-negative, cellular INI1 expression levels are reduced to varying de-
grees in SS, likely reflecting the variable tazemetostat treatment outcomes in SS
[49•] The first results of a phase II trial with tazemetostat in SS and INI1-
negative tumors have been presented at the annual meeting of ASCO 2017
(NCT02601950) [50]. In 33 treated SS patients with a median of two prior
systemic treatments, best response was SD in 11 patients (33%) in which 5
patients lasted ≥ 16 weeks. No objective responses were observed. The protocol-
defined success criterion at the end of study was not met. Additional studies
examining tazemetostat efficacy in SS are currently ongoing. A phase II trial with
vorinostat in 40 STS patients including three SS showed no objective responses,
a median PFS of 3.2 months and median OS of 12.3 months [51].
Immunotherapy
In the field of immunotherapy, the use of engineered T cells directed
against the NY-ESO-1 cancer/testis antigen, which is expressed in 80% of
SS patients, has been the most promising approach in SS in clinical
testing so far [52•]. Objective responses were reported in 4/6 heavily pre-
treated, metastatic, NY-ESO-1-expressing SS patients treated with
lymphodepleting preparative chemotherapy followed by autologous T
cells transduced with an NY-ESO-1-reactive T cell receptor, including
tumor regressions. Long-term follow-up of these patients confirmed ob-
jective responses in 11/18 SS patients (61%), including long-lasting par-
tial and complete responses [53, 54]. A subsequent multi-cohort study
with an updated protocol investigated effects of genetically engineered
NY-ESO-1c259T cells recognizing an NY-ESO-1 derived peptide
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complexed with HLA-A2 in advanced, NY-ESO-1-positive SS patients. So
far, promising efficacy and acceptable safety data have been demonstrat-
ed, including 1 CR and 5 PRs in the 12 treated SS patients of the first
study cohort [65]. Interestingly, further data presented by D’Angelo at the
annual meeting of CTOS 2017 reported responses in all four study
cohorts, and the addition of fludarabine appeared to be required for
optimal therapy response. Of note, in early 2016, the FDA granted
breakthrough therapy designation for the affinity enhanced T cell therapy
targeting NY-ESO for SS in the advanced setting and expressing NY-ESO-1
and HLA-A2 alleles. A variety of other clinical studies employing NY-ESO-
1 in SS are currently under way (e.g., NCT02457650, NCT01343043).
The results of the Alliance A091401 study with the the PD1-inhibitor
nivolumab and the combination of nivolumab and the CTLA4-inhibitor
ipilimumab tested in 85 STS patients, included 4 SS patients. Objective re-
sponses were reported in 5% of patients treated with single-agent nivolumab
and in 16% of the patients treated with the combination. No response was seen
in SS. Median PFS and OS was 2.6 and 8.7 months for the single-agent
nivolumab cohort and 4.5 and 11.2 months for the combination cohort
(NCT02500797) [66••]. A second trial presented at ASCO 2017 combined
low oral doses of cyclophosphamide with anti-PD1 pembrolizumab in differ-
ent types of STS and GIST. In 50 evaluable patients, only three PRs were
observed and very limited progression-free survival rates (NCT02406781)
[67]. In the SARC028 study, pembrolizumab was administered in 85 patients
with bone and soft tissue sarcoma, including 10 SS patients. For STS, median
follow-up was 14.5 months. The objective response rate in the overall STS
cohort was 18% and the 12-week PFR 55%. One out of 10 SS patients had a
PR [68••]. An ongoing phase I–II trial combining pembrolizumab with doxo-
rubicin in advanced or metastastic STS is currently recruiting patients
(NCT02888665), as is a phase II study of Talimogene Laherparepvec (T-VEC)
combined with pembrolizumab (NCT03069378). In the neoadjuvant setting,
anti-PD-L1 (Durvalumab/MEDI4736) plus anti-CTLA-4 (Tremelimumab) and
radiation is tested for high-risk STS (NCT03116529). The combination of RTK
inhibitor axitinib and pembrolizumab is currently tested in specific types of STS
including SS, after failure of anthracyclines (NCT02636725). As a first-line
therapy, the combination of trabectedin, nivolumab, and anti-CTLA-4
ipilimumab is under investigation in a dose-finding phase I–II study for ad-
vanced STS (NCT03138161). A phase I trial in STS including SS with decitabine
and autologous cancer testis antigen-specific dendritic cell vaccine has recently
completed accrual (NCT01241162).
In conclusion, although it is too early to conclude on the efficacy of immu-
notherapy in SS, therapy based on engineered T cells showed exciting early
results. The SARC028 trial reported one PR in SS [68••].
Promising preclinical targeted therapies
Although as mentioned above, various preclinical studies have failed to
translate into a significant benefit for SS patients, there are some remarks
to make concerning both the set-up of these studies, as well as on the
types of therapies included. Most preclinical studies performed in SS to
date that failed to show a benefit in the clinic, were focused on drugs
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specifically aimed at (single) RTKs. This includes research on for example
the targeting of the RTK IGF-1R with monoclonal antibodies, in which
preclinical promising data did not translate into encouraging results in
the subsequently executed four phase II clinical trials [41–44]. On re-
flection, this is not necessarily an unexpected result, as it has since been
shown that SS only rarely depend on a single RTK for growth and harbor
little to no recurrent mutations that could be associated with a driver
signature [69•, 70•]. However, when combined with biomarkers capable
of adequately identifying driver (RTK) signatures, implementation of such
treatments could potentially translate into a clinical benefit in preselected
subgroups of patients with a positive biomarker. The potential and proof-
of-concept of such an approach was published recently, in which a global
phosphoproteomics approach was used to identify activated targets and
pathways in sarcoma. This approach identified the RTKs ALK and MET to
be the drivers of 2/4 included SS cell lines, irrespective of the SS18-SSX
driver, and pharmacological inhibition of these targets with clinically
relevant inhibitors—such as crizotinib—dramatically affected SS tumor
growth in vitro, and even led to complete tumor regressions in vivo. As in
clinical SS specimens, these key driver signatures were also detected,
albeit only in a small subset of patients, these (types of) therapies are
likely only beneficial to a small subset of SS patients [69•]. In this light,
other lines of (preclinical) research have aimed at ways to either directly
or indirectly target the known driver characterizing SS, the SS18-SSX
fusions. As SS18-SSX fusion genes have been shown to affect gene ex-
pression in an epigenetic fashion, the use of epigenetic-modifying com-
pounds have been investigated in SS [71, 72]. Preclinically, the HDAC
inhibitors vorinostat and quisinostat, and the EZH2 inhibitor
tazemetostat were shown to specifically target SS in an SS18-SSX-
dependent fashion [73–75]. Indeed, in the clinic, tazemetostat did show
efficacy in SS patients as pointed out in the sections above, supporting
the rationale to further investigate (combined) treatment regimens with
tazemetostat, but also underlining the need to investigate the clinical
potential of (other) epigenetic modifiers in SS. As mentioned before, the
phase II study of vorinostat in refractory STS did not report an objective
response in the three included SS patients [51], but a combination with
for example the proteasome inhibitor bortezomib showed synergistic
efficacy in SS models in vitro and in vivo and might be interesting [73].
Also, very recently, a synthetic lethal interaction was reported between the
presence of the SS18-SSX fusion oncogene and sensitivity to inhibitors
directed against the DNA damage response (DDR) kinase, ATR [76••].
Synergistic anti-tumor effects were further observed when combining the
clinically relevant ATR inhibitor VX970 with PARP inhibitors or cisplatin,
of which the latter combination was further examined in vivo and indeed
enhanced SS tumor growth inhibition. As it was suggested that the
presence of SS18-SSX fusions might introduce a vulnerability of these
tumors to DDR inhibitors in general by creating a replication fork stress
phenotype, and various DDR inhibitors are currently in clinical testing for
other malignancies with encouraging results in certain histologies, this
represents an interesting line of investigation that warrants further pre-
clinical and clinical examination for SS [77]. In line with this hypothesis,
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specific sensitivity of SS cell lines to a variety of PARP inhibitors, in-
cluding the clinically relevant compounds olaparib, talazoparib. and
rucaparib, has been reported [76••, 78].
Conclusion
Synovial sarcoma is an intriguing disease, which is relatively chemosensitive to
standard first-line treatment and pazopanib and in a subset possibly also to
other RTK inhibitors. It is still early days for epigenetic modulators, and im-
munotherapy, but successes are observed. Based on preclinical research, DDR
inhibitors should also be tested in clinical studies.
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